8.7 C
Glasgow
Tuesday, March 24, 2026
spot_img

More News

New mechanism driving breast cancer progression

Jim Cornall -
A research group led by Cecilia Sahlgren at Åbo Akademi University in Finland and the InFLAMES Research Flagship has...

Mutation strength in a single gene shapes tumour behaviour

Jim Cornall -
Cancer is often thought of as a single disease. Yet even tumours that arise in the same organ can...

Base to Base biotech podcast 51: Ovarian cancer, blue crayfish, and stopping brittle bone disease  

Jim Cornall -
On this week’s episode, we chat with Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and director...

EDPB and EDPS support harmonisation of clinical trials under European Biotech Act

Jim Cornall -
The European Data Protection Board (EDPB) and the European Data Protection Supervisor (EDPS) have adopted a Joint Opinion on...

IND clearance for focal epilepsy cell therapy

Jim Cornall -
Unixell Biotech’s UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the...

New data on achondroplasia presented

Jim Cornall -
BioMarin Pharmaceutical Inc. has announced positive new data from studies of VOXZOGO (vosoritide) in children with achondroplasia in ongoing...

GenScript opens European mRNA hub

Jim Cornall -
GenScript has officially opened its first European mRNA production site in Delft, the Netherlands. The Delft facility strengthens GenScript's transatlantic...

Fast Track Designation for myotonic dystrophy type 1 drug

Jim Cornall -
ARTHEx Biotech has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ATX-01...

Fast Track Designation for Netherton syndrome treatment

Jim Cornall -
Quoin Pharmaceuticals Ltd. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to...

New preclinical data for POLG disease treatment

Jim Cornall -
Pretzel Therapeutics has presented new preclinical data on the lead therapeutic in its bioenergetics restoration franchise, PX578, at the...

Enodia Therapeutics acquires preclinical assets from Kezar Life Sciences

Jim Cornall -
Enodia Therapeutics has acquired Kezar Life Sciences’ assets from its Sec61-based discovery and development programme. The acquisition enables Enodia to...

Baseimmune expands into fibrosis

Jim Cornall -
Baseimmune has unveiled its new fibrosis-focused pipeline, beginning with idiopathic pulmonary fibrosis (IPF). IPF is a progressive and life-threatening condition...

Capsule technology opens new window into individual cells

Jim Cornall -
Researchers have developed a capsule-based method that makes it possible to analyse the same cell through multiple experimental steps....

SteerBio launches to find curative therapy for lymphedema

Jim Cornall -
RBL LLC has announced that its portfolio company SteerBio, a biotech startup developing a first-of-its-kind regenerative treatment aimed at...

Severe atopic dermatitis drug sees positive study results

Jim Cornall -
Pfizer Inc. has announced positive topline results from a phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate...

Base to Base biotech podcast 50: Drugs for kidney transplants, glycans, and  drug delivery

Jim Cornall -
As this week’s podcast comes hot on the heels of International Women’s Day and World Kidney Day, which was...

Anti-cancer drug gets phase I FDA trials approval

Jim Cornall -
Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) says its independently developed novel epigenetic immunoactivator GNTbm-38, for cancer immunotherapy,...

New mass spec platform launched

Jim Cornall -
Nicoya Lifesciences, Inc. has launched FastHDX, a new hydrogen-deuterium exchange mass spectrometry (HDX-MS) platform. FastHDX is the first platform engineered...

Approval for prostate cancer treatment

Jim Cornall -
Johnson & Johnson has announced that the European Commission (EC) has approved an indication extension for AKEEGA (niraparib and...

Approval for atopic dermatitis treatment

Jim Cornall -
Harbour BioMed and Kelun-Biotech have announced that the National Medical Products Administration (NMPA) of China has approved the Investigational...

FDA Breakthrough Therapy Designation for Glanzmann Thrombasthenia drug

Jim Cornall -
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Hemab Therapeutics’ drug sutacimig for...

Deeptech Digest is your guide to what's new in at the cutting edge of science technology. A bit of artificial intelligence, some biotech, and all the news and latests developments in the field. If it's deeptech, it's in Deeptech Digest!

Contact us: jim@deeptechdigest.com

© 2023 Ayr Coastal Media